Your browser is no longer supported. Please, upgrade your browser.
Lucira Health, Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own35.90% Shs Outstand44.92M Perf Week-22.32%
Market Cap318.93M Forward P/E- EPS next Y-0.60 Insider Trans27.33% Shs Float36.12M Perf Month-50.28%
Income-22.20M PEG- EPS next Q-0.38 Inst Own35.15% Short Float1.72% Perf Quarter-
Sales0.27M P/S1185.62 EPS this Y-29.50% Inst Trans- Short Ratio0.83 Perf Half Y-
Book/sh- P/B- EPS next Y42.30% ROA- Target Price- Perf Year-
Cash/sh1.52 P/C4.67 EPS next 5Y- ROE- 52W Range6.66 - 37.99 Perf YTD-71.58%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.52% Beta-
Dividend %- Quick Ratio12.00 Sales past 5Y- Gross Margin- 52W Low5.39% ATR1.14
Employees57 Current Ratio12.00 Sales Q/Q- Oper. Margin- RSI (14)32.17 Volatility10.07% 12.43%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.64 Prev Close7.10
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume749.27K Price7.02
Recom2.00 SMA20-27.22% SMA50-56.24% SMA200-58.01% Volume92,140 Change-1.14%
Apr-13-21Downgrade BofA Securities Neutral → Underperform $9
Mar-02-21Initiated William Blair Outperform
Mar-02-21Initiated BofA Securities Neutral $22
Apr-22-21 03:49PM  
Apr-13-21 08:12PM  
Apr-12-21 05:30PM  
Apr-09-21 06:00AM  
Feb-11-21 06:00AM  
Feb-09-21 04:05PM  
Feb-05-21 05:26PM  
Feb-04-21 11:27PM  
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EPIQ Capital Group, LLC10% OwnerFeb 05Buy17.003,461,76458,849,9883,461,764Feb 09 06:39 PM